Why Merck (MRK) Dipped More Than Broader Market Today
In the latest close session, Merck (MRK) was down 2.66% at $145.31. The stock fell short of the S&P 500, which registered a loss of 0.25% for the day. Elsewhere, the Dow saw a downswing of 0.86%, while the tech-heavy Nasdaq appreciated by 0.24%.
Coming into today, shares of the pharmaceutical company had lost 0.39% in the past month. In that same time, the Medical sector lost 1.01%, while the S&P 500 lost 0.42%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on October 29, 2026. The company's upcoming EPS is projected at $2.25, signifying a 12.79% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $17.52 billion, up 1.39% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.77 per share and a revenue of $67.25 billion, signifying shifts of -69.15% and +3.44%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Merck. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.07% lower. At present, Merck boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 53.99. This represents a premium compared to its industry average Forward P/E of 16.43.
We can also see that MRK currently has a PEG ratio of 6.49. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 2.09.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpMerck & Co., Inc. (MRK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
